ABSTRACT
Objective@#This study determined the efficacy of calcitonin gene-related peptide (CGRP) antagonists in the treatment of acute migraine.
Subject(s)
Humans , Calcitonin Gene-Related Peptide , Migraine Disorders , Tryptamines , PainABSTRACT
Objective: This study determined the efficacy of calcitonin gene-related peptide (CGRP) antagonists in the treatment of acute migraine.Methods: Seven randomized, controlled trials were included. Outcome measures used were pain freedom and pain relief two hours after treatment.Results: The difference in pain freedom 2 hours post-dose significantly favored gepants 140/150 mg (OR=2.39, 95% CI=1.93-2.96, PConclusion: With regard to pain freedom and pain relief two hours post-dose, CGRP antagonists are more efficacious than placebo in the treatment of acute migraine but there is insufficient evidence to demonstrate superior efficacy of CGRP antagonists over triptans.